Ocular Therapeutix, Inc.
OCUL
$11.87
-$0.43-3.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.26% | -0.33% | 9.03% | 6.45% | 11.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.26% | -0.33% | 9.03% | 6.45% | 11.90% |
| Cost of Revenue | 105.98% | 114.42% | 100.89% | 71.57% | 40.03% |
| Gross Profit | -379.37% | -659.67% | -780.91% | -743.44% | -256.14% |
| SG&A Expenses | 32.75% | 26.44% | 25.58% | 12.19% | 4.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.67% | 68.56% | 61.05% | 39.16% | 20.37% |
| Operating Income | -115.68% | -113.64% | -97.95% | -62.26% | -25.88% |
| Income Before Tax | -56.65% | -67.19% | -139.68% | -159.98% | -52.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.65% | -67.19% | -139.68% | -159.98% | -52.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.65% | -67.19% | -139.68% | -159.98% | -52.50% |
| EBIT | -115.68% | -113.64% | -97.95% | -62.26% | -25.88% |
| EBITDA | -119.72% | -117.57% | -100.62% | -62.62% | -24.62% |
| EPS Basic | -15.32% | -3.59% | -25.00% | -52.56% | 5.54% |
| Normalized Basic EPS | -24.98% | -1.89% | 16.04% | -1.13% | 12.82% |
| EPS Diluted | 5.44% | 15.02% | -0.56% | -15.20% | -12.15% |
| Normalized Diluted EPS | -26.52% | -3.08% | 15.15% | -3.77% | 12.84% |
| Average Basic Shares Outstanding | 46.65% | 79.27% | 98.24% | 76.15% | 49.20% |
| Average Diluted Shares Outstanding | 44.84% | 76.54% | 94.72% | 69.87% | 48.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |